Shares of InMed Pharmaceuticals Inc. (INM) jumped nearly 20% on Tuesday morning after the company announced that INM-901 demonstrates statistically significant reduction in neuroinflammation in a long-term preclinical alzheimer's disease study.
INM is currently trading at $5.85, up $0.94 or 19.17%, on a huge volume of 23 million shares, above average volume of 40 thousand, on the Nasdaq. The stock opened its trading at $7.23 after closing Friday at $4.91. The stock has traded between $2.42 and $15.70 in the past 52-week period.
In the study, INM-901 demonstrated a reduction in several plasma and brain markers of neuroinflammation, a recognized contributor to Alzheimer's disease development and progression.
Dr. Eric Hsu, InMed's SVP of Preclinical R&D, commented, "We are highly encouraged by the data from our long-term preclinical study of INM-901. Overall, our data showed a reduction of several neuroinflammation markers in an amyloid-induced Alzheimer's disease model, suggesting that INM-901 may lower neuroinflammation."
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.